Purple Biotech (PPBT) Total Non-Current Liabilities (2016 - 2026)
Purple Biotech (PPBT) reported Total Non-Current Liabilities of $160000.0 for Q1 2026, up 14.29% year-over-year from $140000.0 in Q1 2025, and little changed quarter-over-quarter from $160000.0 in Q4 2025.
Purple Biotech (PPBT) Total Non-Current Liabilities (2016 - 2026) Analysis & Trends
Purple Biotech (PPBT) has 11 years of Total Non-Current Liabilities data on file, last reported at $160000.0 in Q1 2026.
- Total Non-Current Liabilities for Q1 2026 came in at $160000.0, up 14.29% year-over-year; the trailing twelve-month figure through Mar 2026 was $160000.0 (up 14.29% YoY), and the FY2025 annual result was $160000.0, up 14.29% from the prior year.
- Total Non-Current Liabilities held at $160000.0 in Q1 2026 per PPBT's latest filing, from $160000.0 in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $787000.0 in Q1 2022 and troughed at $140000.0 in Q4 2024.
- A 5-year average of $321705.9 and a median of $262000.0 in 2024 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities plunged 53.95% in 2024, then grew 14.29% in 2025.
- A 5-year view of Total Non-Current Liabilities shows it stood at $466000.0 in 2022, then plunged by 34.76% to $304000.0 in 2023, then sank by 53.95% to $140000.0 in 2024, then grew by 14.29% to $160000.0 in 2025, then changed by 0.0% to $160000.0 in 2026.
- Business Quant data shows PPBT's Total Non-Current Liabilities at $160000.0 in Q1 2026, $160000.0 in Q4 2025, and $189000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | 42,980.09 |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 64.76 Mn |
| 10 | Purple Biotech | 242.86 Mn | 236.43 Mn | - | 160,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 160,000.00 |
| Dec 31, 2025 | 160,000.00 |
| Sep 30, 2025 | 189,000.00 |
| Jun 30, 2025 | 140,000.00 |
| Mar 31, 2025 | 140,000.00 |
| Dec 31, 2024 | 140,000.00 |
| Sep 30, 2024 | 179,000.00 |
| Jun 30, 2024 | 220,000.00 |
| Mar 31, 2024 | 262,000.00 |
| Dec 31, 2023 | 304,000.00 |
| Sep 30, 2023 | 333,000.00 |
| Jun 30, 2023 | 378,000.00 |
| Mar 31, 2023 | 419,000.00 |
| Dec 31, 2022 | 466,000.00 |
| Sep 30, 2022 | 501,000.00 |
| Jun 30, 2022 | 691,000.00 |
| Mar 31, 2022 | 787,000.00 |
| Dec 31, 2021 | 842,000.00 |
| Sep 30, 2021 | 828,000.00 |
| Jun 30, 2021 | 870,000.00 |